Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
出版年份 2021 全文链接
标题
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-07
DOI
10.1186/s13045-021-01049-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
- (2020) Jennifer Woyach et al. BLOOD
- BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
- (2020) Sasanka M. Handunnetti et al. BLOOD
- LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL
- (2020) Aishath S Naeem et al. BLOOD
- Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
- (2020) Ola A. Elgamal et al. Journal of Hematology & Oncology
- Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
- (2020) Wei Xu et al. Journal of Hematology & Oncology
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
- (2020) Hong Zhou et al. OncoTargets and Therapy
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
- (2019) Deborah M. Stephens et al. BLOOD
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic alterations and their clinical implications in DLBCL
- (2019) Yi Miao et al. Nature Reviews Clinical Oncology
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
- (2019) Liang Zhang et al. Science Translational Medicine
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant Btk C481S mutation in B‐cell malignancies
- (2019) Fu Gui et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines
- (2019) Xiaofeng Guo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
- (2019) Matthew S Davids et al. Lancet Haematology
- PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
- (2019) Xiuyun Sun et al. BIOCHEMISTRY
- Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
- (2019) Wei Xu et al. BLOOD
- Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
- (2019) Eliana B. Gomez et al. BLOOD
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
- (2019) John N. Allan et al. BLOOD
- The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
- (2019) Debora Soncini et al. HAEMATOLOGICA
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Non-covalent inhibition of C481S Bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL
- (2018) Sean D. Reiff et al. BLOOD
- Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
- (2018) Oshrat Hershkovitz-Rokah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
- (2018) Ann E. Herman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
- (2018) Jun Chen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
- (2018) John C. Byrd et al. Oncotarget
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
- (2018) Barbara Brandhuber et al. Clinical Lymphoma Myeloma & Leukemia
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
- (2018) Ana Colado et al. Blood Cancer Journal
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
- (2017) Alexander N. R. Weber et al. Frontiers in Immunology
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function
- (2016) Rachel A. Rigg et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
- (2016) Nakhle S. Saba et al. BLOOD
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
- (2016) F. Scherer et al. Science Translational Medicine
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
- (2016) Atish Mohanty et al. Oncotarget
- CD79B limits response of diffuse large B cell lymphoma to ibrutinib
- (2015) Joo Hyun Kim et al. LEUKEMIA & LYMPHOMA
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia
- (2014) Y Cao et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- The Src, Syk, and Tec family kinases: Distinct types of molecular switches
- (2010) J. Michael Bradshaw CELLULAR SIGNALLING
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- (2010) Julie A Di Paolo et al. Nature Chemical Biology
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation
- (2009) Lynette Pretorius et al. AMERICAN JOURNAL OF PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now